Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer

Descripción del Articulo

Triple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathwa...

Descripción completa

Detalles Bibliográficos
Autores: de, Mello, RAB, Perez, KR, Vazquez, TP
Formato: revisión
Fecha de Publicación:2024
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:20.500.14703/390
Enlace del recurso:https: //doi.org/10.2217/imt-2022-0277
https://hdl.handle.net/20.500.14703/390
Nivel de acceso:acceso abierto
Materia:breast cancer
immunotherapy
neoadjuvant treatment
new targets
triple negative
https://purl.org/pe-repo/ocde/ford#3.02.21
id INEN_555061de9095cdf534e2ef97972aaada
oai_identifier_str oai:repositorio.inen.sld.pe:20.500.14703/390
network_acronym_str INEN
network_name_str INEN-Institucional
repository_id_str .
spelling Publicationde, Mello, RABPerez, KRVazquez, TP2025-06-17T17:29:41Z2025-06-17T17:29:41Z2024https: //doi.org/10.2217/imt-2022-0277https://hdl.handle.net/20.500.14703/390ImmunotherapyTriple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting.application/pdfengNewlands Press LtdUKinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/breast cancerimmunotherapyneoadjuvant treatmentnew targetstriple negativehttps://purl.org/pe-repo/ocde/ford#3.02.21Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancerinfo:eu-repo/semantics/reviewinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INEN20.500.14703/390oai:repositorio.inen.sld.pe:20.500.14703/3902026-02-12T00:40:21.137Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessmetadata.onlyhttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.pe
dc.title.none.fl_str_mv Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
title Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
spellingShingle Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
de, Mello, RAB
breast cancer
immunotherapy
neoadjuvant treatment
new targets
triple negative
https://purl.org/pe-repo/ocde/ford#3.02.21
title_short Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
title_full Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
title_fullStr Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
title_full_unstemmed Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
title_sort Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
author de, Mello, RAB
author_facet de, Mello, RAB
Perez, KR
Vazquez, TP
author_role author
author2 Perez, KR
Vazquez, TP
author2_role author
author
dc.contributor.author.fl_str_mv de, Mello, RAB
Perez, KR
Vazquez, TP
dc.subject.none.fl_str_mv breast cancer
immunotherapy
neoadjuvant treatment
new targets
triple negative
topic breast cancer
immunotherapy
neoadjuvant treatment
new targets
triple negative
https://purl.org/pe-repo/ocde/ford#3.02.21
dc.subject.ocde.none.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.02.21
description Triple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2025-06-17T17:29:41Z
dc.date.available.none.fl_str_mv 2025-06-17T17:29:41Z
dc.date.issued.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/review
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format review
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv https: //doi.org/10.2217/imt-2022-0277
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.14703/390
dc.identifier.journal.none.fl_str_mv Immunotherapy
url https: //doi.org/10.2217/imt-2022-0277
https://hdl.handle.net/20.500.14703/390
identifier_str_mv Immunotherapy
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Newlands Press Ltd
dc.publisher.country.none.fl_str_mv UK
publisher.none.fl_str_mv Newlands Press Ltd
dc.source.none.fl_str_mv reponame:INEN-Institucional
instname:Instituto Nacional de Enfermedades Neoplásicas
instacron:INEN
instname_str Instituto Nacional de Enfermedades Neoplásicas
instacron_str INEN
institution INEN
reponame_str INEN-Institucional
collection INEN-Institucional
repository.name.fl_str_mv Repositorio del Instituto Nacional de Enfermedades Neoplásicas
repository.mail.fl_str_mv repositorio@inen.sld.pe
_version_ 1868438561428078592
score 12.821158
Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares